Study identifier:BY9010/M1-125
ClinicalTrials.gov identifier:NCT00546520
EudraCT identifier:N/A
CTIS identifier:N/A
A 3-period double-blind, cross-over study on the onset of action of inhaled ciclesonide (7 days of 400 mcg sid versus 800 mcg bid versus placebo) on airway responsiveness to adenosine monophosphate (AMP), sputum eosinophiles and exhaled breath nitric oxide (NO) in patients with asthma
asthma
Phase 3
No
Ciclesonide
All
21
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Feb 2017 by AstraZeneca
AstraZeneca
-
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be evaluated.
Location
Location
London, United Kingdom, SW3 6NP
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.